Protecting children and older adults from invasive pneumococcal disease

Posted Wednesday 30 October 2024 | Immunisation Coalition

This event aimed to highlight Professor Cripps’ key achievements and shed light on the advancements in diagnosis, treatment, and prevention of pneumococcal disease.

Our expert panel discussed pneumococcal disease, vaccine development, and the impact of vaccines on disease reduction in both adults and children. They also discussed the different serotypes and their effects across age groups, provided insights into invasive pneumococcal disease, immunisation recommendations, and compared polysaccharide and conjugated vaccine types.

The panel reviewed valent options and the future pneumococcal immunisation program for reducing disease burden. Additionally, strategies to increase immunisation rates among older adults and high-risk groups were covered.